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Chronic brucellosis patients display a defective Th1 response to PHA. We have previously shown that heat-killed B. abortus
(HKBA) can downregulate the PHA-induced increase of CD4+/CD25+ and CD14+/CD80+ cells of brucellosis patients. In the
present study, we investigate the eﬀect of E. coli LPS, as a potent stimulant of monocytes and autologous T-lymphocytes, on
the PHA-cultured PBMCs of the same groups of patients. Thirteen acute brucellosis (AB) patients, 22 chronic brucellosis (CB)
patients, 11 “cured” subjects, and 15 healthy volunteers were studied. The percentage of CD4+/CD25+ and CD4+/CD28+ T-
lymphocytes as well as CD14+/CD80+ monocytes were analyzed by ﬂow cytometry after PBMCs culture with PHA plus E. coli
LPS. A signiﬁcant decrease in the percentage of CD4+/CD25+ and CD4+/CD28+ T-lymphocytes was observed in CB compared
to AB. In HKBA cultures, compared to E. coli LPS-cultures, there was a signiﬁcant reduction of CD4+/CD25+ T-lymphocytes in
all groups and CD14+/CD80+ in patients groups. We suggest that Brucella can modulate host immune response, leading to T-cell
anergy and chronic infection.
Copyright © 2008 Panagiotis Skendros et al. This is an open access article distributed under the Creative Commons Attribution




wide distribution. More than 500000 new cases are reported
annually [1, 2]. It is caused by intracellular pathogens
of the genus Brucella that have their natural reservoir in
domestic and wild animals [1]. The disease is transmitted to
humans by consumption of contaminated dairy products or
by occupational contact with infected animals. In addition,
Brucella species are thought to be a biowarfare agent and
recently reported to be a signiﬁcant cause of travel and
immigration-related infection [1, 3–5].
In Greece, as in other Mediterranean countries, bru-
cellosis remains a major disease of economic and human
health importance despite eﬀorts for animal control and
eradication projects [2, 4]. Besides minimal brucellosis mor-
tality in humans, the disease causes high clinical morbidity,
protean clinical manifestations, and complications, as any
organ can be aﬀected [1, 6, 7]. Despite early diagnosis
and treatment, approximately 10–30% of patients develop
chronic persistence disease which is characterized by atypical
clinicalpicture,chronicfatiguesyndrome,andrelapses[4,6–
8].
Host protection against Brucella spp. depends on
cell-mediated immunity, involving mainly activated
macrophages, dendritic cells, and T-cells [9–13]. T-helper
1 (Th1) immune response is essential for the clearance
of Brucella infection and Brucella antigens induce the
production of Th1 cytokines in humans [9–11, 14]. On
the other hand, Brucella can survive and replicate in
host macrophages and dendritic cells subverting innate
immunity and evading adaptive immune mechanisms
[8, 12, 13, 15, 16]. Recent data report that human dendritic
cells infected by living Brucellae are poor inducers of
human na¨ ıve T-lymphocyte proliferation and present
low production of interleukin (IL)-12 which is essential
t od r i v eaT h 1i m m u n er e s p o n s e[ 13, 16]. Diminished
production of Th1 cytokines (IFNγ and IL-2) has been2 Clinical and Developmental Immunology
associated with T-cell unresponsiveness (anergy) to
Brucella antigens and disease chronicity [17–19]. In
addition, proliferation response of CD4+ T-lymphocytes to
phytohaemagglutinin (PHA) in chronic brucellosis patients
was found to be signiﬁcantly low [20]. Recently, we have
shown low frequency of ex vivo and PHA-cultured CD4+
T-lymphocytes expressing IL-2 receptor alpha (CD25) in
chronic brucellosis patients [21].
CD80/CD28 costimulation enhances the interaction of
antigen/major histocompatibility complex (MHC) with T-
cell receptor (TCR) and is critical for an adequate induction
and maintenance of the Th1 response [22]. When we
studied CD80/CD28 costimulation in human brucellosis, it
was indicated that heat-killed B. abortus (HKBA) signiﬁ-
cantly downregulated the PHA-induced increase of CD80+
monocytes [23]. This eﬀect could be attributed to Brucella
lipopolysaccharide (LPS) which is thought to be one of the
virulence factors that endow the pathogen with the ability
to escape the immune [8, 15, 24]. Brucella smooth LPS
is considered to be very important for bacterium survival
and replication in the host [24–26]. It is an unconventional,
nonendotoxic LPS, as compared with classical LPS from
enterobacteria such as E. coli [27]. Enterobacteria LPS is
a potent stimulant of monocytes for the production of
proinﬂammatory cytokines (such as tumor necrosis factor
(TNF)α,I L - 1 β) and the expression of CD80 [28]. Moreover,
it induces the IFNγ secretion, as well as, the upregulation of
CD25 and CD28 by autologous T-lymphocytes [29–32].
Thus, we decided to investigate the inﬂuence of E. coli
LPS on CD25 expression and CD80/CD28 costimulation
of PHA-stimulated peripheral blood mononuclear cells
(PBMCs)frombrucellosispatients andcomparetheﬁndings
with our previous results regarding the HKBA stimulation of
PBMCs in the same groups of patients [23].
2. MATERIALS AND METHODS
2.1. Subjects
Sixty one unrelated subjects were included in the study: (a)
35 brucellosis patients; (b) 11 subjects who had a previous
history of brucellosis and were cured at least 2 years ago; (c)
15 healthy age- and gender-matched volunteers who were
used as controls. Patients were divided in acute (AB) and
chronic (CB) brucellosis groups according to disease history,
clinical picture, and laboratory ﬁndings [21, 23].
The AB group included 13 consecutive patients
(Table 1). All AB patients had a disease duration ≤8w e e k s
(mean ± SD, 3.9 ± 2.6 weeks). The diagnosis was based on
a compatible clinical picture (Table 2) in combination with
high serum titres of antibrucellar antibodies or a fourfold
increase of the initial titres in two-paired samples drawn 2
weeks apart. In addition, in 6 out of 13 AB patients, Brucella
melitensis was isolated in blood culture. In 2 patients,
brucellar DNA was detected by PCR analysis in the blood
and the serum.
The CB group comprised 22 patients (Table 1). All CB
patients had a disease duration ≥12 months. Twelve patients
were suﬀering from the relapsing type of chronic disease
(CB1 subgroup, mean disease duration 36.3 ± 18.8 months)
which is characterized by periodic attacks of fever, chills,
and arthalgias/myalgias [6, 7, 21, 23] (mean number of
relapses 2.3 ± 0.7). At the time of study entry, CB1 patients
were under relapse in accordance to the clinical picture and
the high titres of antibrucellar antibodies. Nine of 12 CB1
patients had also positive PCR analysis in the blood. The
variable type of the chronic disease was presented by 10 of
the 22 chronic brucellosis patients (CB2 subgroup, mean
diseaseduration32.4±15.9 months).CB2subgrouppatients
experienced no relapses but displayed atypical symptoms
(Table 2) and persistently high serum antibrucellar antibody
titres [6, 7, 21, 23].
High antibrucellar antibody titres were considered for
the Wright agglutination test ≥1:320, for the Coombs
agglutination test ≥1:320, and for the complement ﬁxation
test ≥1:32.
“Cured” from brucellosis subjects (Table 1) remained
symptomless and with negative antibrucellar antibodies for
at least 2 years. Healthy volunteers (Table 1)w e r et e s t e d
serologically for brucellosis and found to be negative.
All CB patients and “cured” subjects had received initial
antibiotic treatment including mainly streptomycin 1gr/day
combined with rifampicin 600mg/day plus doxycycline
200mg/day for 2 weeks and rifampicin 600mg/day plus
doxycycline 200mg/day for 6 to 10 weeks thereafter. In
8 of 22 CB patients and 3 of 11 “cured” individuals,
streptomycin was not administered. In a CB1 patient who
suﬀered from spondylitis (Table 2) treatment lasted for 6
months. In addition, most of CB patients had received
more than one antibiotic course and alternative therapeutic
approaches were used such as cotrimoxazole or ciproﬂoxacin
in combination with doxycycline and/or rifampicin. Patients
with inadequate treatment were not included in the study.
The exclusion criteria of the study were
(i) coexistence of other infectious, neoplasmatic, or
autoimmune disease;
(ii) administration of antibiotic or immunostimulating
agents for at least 30 days before entering the study;
(iii) recent (≤6 months) vaccination;
(iv) pregnancy.
Informed consent was obtained from all subjects enrolled in
the study.
2.2. Cellcultures
Twenty mL heparinized venous blood was collected in sterile
tubes and PBMCs were isolated using density gradient
centrifugation (Histopaque-1007, Sigma Laboratories, St.
Louis, Mo, USA). The viability of PBMCs was determined
to be greater than 95%, as indicated by Trypan blue dye
exclusion (Sigma Laboratories, St Louis, Mo, USA).
We used LPS from E. coli serotype 0111:B4 (Sigma
Laboratories, St. Louis, Mo, USA). This serotype does not
share high antigenic similarity with brucella species [33].
Preliminary experiments in PBMCs from healthy volun-
teers were carried out to standardize the time and dose ofPanagiotis Skendros et al. 3
Table 1: Demographic data of the groups (AB, CB, “cured,” controls) and CB subgroups (CB1, CB2) studied.
AB CB CB1 CB2 Cured Controls
n 13 22 12 10 11 15
F e m a l e 521144
M a l e 82 0 1 19 71 1
Age (mean ± SD, years) 44.7 ±21.44 8 .1 ±15.64 5 .3 ±14.85 1 .6 ±16.65 0 .3 ±16.74 3 .8 ±16.3
Table 2: Clinical characteristics of the patients studied.
Symptoms AB (n = 13) CB1 (n = 12) CB2 (n = 10)
Fever 13 3
Sweating 11 2 1
Chills 9 1
Malaise/fatigue 8 8 9
Arthalgias 6 5 1









PHA and E. coli LPS needed for the optimal expression
of CD25, CD80, and CD28. In accordance with previous
reports, PBMCs were stimulated with 1, 3, and 10μg E. coli
LPS per mL of culture medium [34–36] and no diﬀerences
werenoticedintheexpressionoftheCD80molecule.Finally,
wedecidedtousethe3μg/mLconcentration,asithasalready
been used in another brucellosis study on human monocytes
[34].
PBMCs were cultured in triplicate in the presence of
5μg / m LP H Ap l u s3 μg/mL E. coli LPS in 24-well plates
(Costar, Boston, Mass, USA). PBMCs were 1 × 106 cells
per well of culture plate. Each well contained 1mL of
culture suspension. Culture medium consisted of RPMI-
1640 (Gibco Laboratories, Paisley, UK) supplemented with
10% fetal calf serum (Gibco Laboratories, Paisley, UK),
2mmol/l l-glutamine (Sigma Laboratories, St. Louis, Mo,
USA), 100IU/mL penicillin (Sigma Laboratories, St. Louis,
Mo, USA), and 100mg/mL streptomycin (Sigma Laborato-
ries, St. Louis, Mo, USA). The cultures were kept at 37◦C
in a humidiﬁed 5% CO2 atmosphere for 48 hours. Approx-
imately 3 × 106 cells per mL of sample were pelleted in a
round-bottomed centrifuge tube and washed in RPMI-1640.
The pellet was resuspended and 100mL (∼3 × 105 PBMCs)
was stained immediately with 20μL of the appropriate
monoclonal antibody (MAB). After 15 minutes incubation
at room temperature, the PBMCs were ﬁxed by using
Immunoprep/Q-prep protocol (Coulter, Hialeah, Fla, USA).
The dual staining method (synchronous two-color ﬂuo-
rescence analysis) was used. The MABs included ﬂuorescein
isothiocyanate (FITC)-conjugated anti-CD4 (clone 13B8.2)
and anti-CD80 (clone MAB104) as well as phycoerythrin
(PE)-conjugated anti-CD25 (clone B1.49.9), anti-CD28
(clone CD28.2), and anti-CD14 (clone RMO52). Appropri-
ateisotypecontrolsincludedFITCandPEconjugatesofIgG1
(clone 679.1Mc7) and IgG1 (clone 679.1Mc7) mouse MABs
which were used to assess the nonspeciﬁc binding and to
set the threshold between positively and negatively stained
cell populations. All MABs were obtained from Immunotech
(Marseille, France).
2.3. Flowcytometry
The following parameters were analyzed by ﬂow cytometry
after PBMCs stimulation with PHA plus E. coli LPS:
(i) the percentage of CD4/CD25 and CD4/CD28 dou-
ble-positive T-lymphocytes;
(ii) the percentage of monocytes (CD14) expressing
CD80.
PBMCs suspension was used rather than puriﬁed monocytes
because we intended to investigate the impact of Brucella
infection on monocyte–T-cell interaction (costimulation
from both sides of cell interaction) [23].
For the ﬂow cytometric analysis, EPICS XL (Coulter
Electronics, Hialeah, Fla, USA) was used. Lymphocytes were
gated using forward scatter (FS) versus side scatter (SS)
dot plots. CD45 FITC staining (clone ALB12, Immunotech,
Marseille, France) was used to conﬁrm the purity of the
lymphocyte population (>97%). Monocytes were character-
ized and gated both in an FS versus SS dot plot and in a
dot plot with SS versus PE-labeled CD14 antibody (purity
>90%). At least 5000 lymphocytes and 2000 monocytes were
acquired and analyzed for their ﬂuorescence properties. The
percentages of surface antigen-stained positive cells were
calculated as the percentage of cells that stained above the
ﬂuorescence value obtained by isotype control antibodies.
Only CD14 strongly positive monocytes were analyzed with
respecttopercentageexpressionofCD80FITC.Resultsofthe
mean ﬂuorescence intensity did not provide any additional
information, and are therefore not reported.
2.4. Statisticalanalysis
Parametric statistical tests were applied as the variables were
distributed normally (Kolmogorov-Smirnov test). Data were
analyzed by Student’s t-test or paired t-test (for paired data)
using SPSS software (SPSS Inc., Chicago, Ill, USA) and were
represented as mean ± SD. P-values < .05 were considered
to be statistically signiﬁcant.4 Clinical and Developmental Immunology
Table 3: Percentage of CD4+/CD25+, CD4+/CD28+ lymphocytes, and CD80+ cells of CD14+ population, in PHA-cultures with (a) E. coli
LPS and (b) HKBA (results are presented as mean ± SD). NS: nonsigniﬁcant.
(a) E. coli LPS cultures n %CD4+/CD25+ %CD4+/CD28+ %CD14+/CD80+
AB 13 37.2 ±11.64 3 .4 ±11.34 7 .9 ±19.9
CB 22 27.9 ± 6.93 5 .7 ±8.04 5 .9 ±23.2
Cured 11 30.8 ±12.83 9 .8 ±17.22 1 .8 ±14.4
Controls 15 27.4 ±10.53 6 .5 ±14.92 0 .9 ±12.5
P (AB versus cured) = NS P (AB versus cured) = NS P(AB versus cured) = .002
P (AB versus controls) = .027 P (AB versus controls) = NS P (AB versus controls) < .001
P (CB versus cured) = NS P (CB versus cured) = NS P (CB versus cured) = .001
P (CB versus controls) = NS P (CB versus controls) = NS P (CB versus controls) < .001
P (AB versus CB) = .006 P (AB versus CB) = .024 P (AB versus CB) = NS
CB1 12 26.3 ± 5.93 4 .5 ±8.74 9 .9 ±26.5
CB2 10 29.9 ± 7.93 7 .1 ±7.24 1 .1 ±18.7
P (CB1 versus AB) = .008 P (CB1 versus AB) = .039
P (CB1 versus CB2) = NS
P (CB1 versus controls) = .003
P (CB2 versus controls) = .004
(b) HKBA cultures
AB 13 22.4 ±11.53 5 .9 ±14.53 0 .0 ±20.8
CB 22 24.8 ± 6.53 8 .8 ±11.23 6 .5 ±25.5
Cured 11 24.8 ±14.83 8 .7 ±17.92 0 .9 ±16.7
Controls 15 20.6 ±10.33 5 .6 ±16.91 6 .3 ±13.6
NS NS P (AB versus controls) = .047
P (CB versus controls) = .004
CB1 12 24.9 ± 7.63 8 .3 ±13.34 6 .6 ±26.6
CB2 10 24.7 ± 5.13 9 .3 ±8.72 4 .4 ±18.7
NS NS
P (CB1 versus CB2) = .038
P (CB1 versus cured) = .012
P (CB1 versus controls) = .003
3. RESULTS
There was a signiﬁcant increase in the percentage of
CD4+/CD25+ T-lymphocytes in AB patients compared to
controls (P = .027). On the other hand, a signiﬁcant
decrease in the percentage of CD4+/CD25+ T-lymphocytes
w a so b s e r v e di nC Bg r o u po fp a t i e n t sc o m p a r e dt oA B
(P = .006) (Table 3(a)).
Concerning CD4+/CD28+ T-lymphocytes, no diﬀer-
ences were found between AB patients and “cured” subjects
or controls. Similarly, CD4+/CD28+ T-lymphocytes in CB
patients did not signiﬁcantly diﬀer in comparison to nonpa-
tients groups. When CB group of patients compared to AB,
a signiﬁcant decrease in the percentage of CD4+/CD28+ T-
lymphocytes of CB was observed (P = .024) (Table 3(a)).
T-lymphocytes subsets did not signiﬁcantly diﬀer
between the CB1 and CB2 subgroups, however the dimin-
ished percentage of CD4+/CD25+ T-lymphocytes in CB
patients was related to the CB1 subgroup (P = .008).
In the same manner, CB1 patients showed signiﬁcantly
lower frequency of CD4+/CD28+ T-lymphocytes (P = .039)
(Table 3(a)).
Regarding the frequency of CD14+ monocytes express-
ing CD80 costimulation molecule, a signiﬁcant increase was
foundinbothofbrucellosisgroupsincomparisonto“cured”
(P = .002 and .001, resp.) and controls (P < .001).
No diﬀerences of the percentage of CD80+ monocytes
were observed between the CB1 and CB2 subgroups. How-
ever, there was a signiﬁcant increase in the percentage of this
cellular population between both subgroups of CB patients
and controls (P = .003 and .004, resp.) (Table 3(a)).
We compared the above results with the ﬁndings yielded
from our previous studies (on the same cultured PBMCs
stimulated simultaneously with PHA alone or PHA plus
HKBA, Figure 1)[ 21, 23]. The results between PHA alone
and PHA plus E. coli LPS-cultured PBMCs were similar. On
thecontrary,whenHKBA-cultures,comparedto E.coli LPS-
cultures, there was a signiﬁcant reduction of CD4+/CD25+
T-lymphocytes in all groups (AB P = .005, CB P = .042,
“cured” P = .029, controls P = .007) and CD14+/CD80+
monocytes in patients groups (AB P < .001, CB P = .05)
(Figure 1).
4. DISCUSSION
Brucella acquires the ability to establish chronic infection
and has evolved strategies to actively modulate the hostPanagiotis Skendros et al. 5









































































CD14+/CD80+ monocytes in brucellosis patients. Data represent mean values+SD (SE). #P ≤ .05; PHA versus PHA + E. coli LPS, ∧P ≤ .05;
∧∧P<.001; PHA versus PHA + HKBA, ∗P ≤ .05; ∗∗P < .001; PHA + E. coli LPS versus PHA + HKBA.
immune response [8, 10, 13, 15, 16]. Chronic brucellosis
patients display a defective Th1 response to PHA character-
ized by low-proliferation response of CD4+ T-lymphocytes,
diminished production of IL-2 and IFNγ,a n dl o wf r e q u e n c y
of CD4+/CD25+ T-cells compared to acute brucellosis
patients [17–21]. In this study, we investigated the eﬀect of
a potent monocytic stimulant (E. coli LPS) on the PHA-
cultured PBMCs of patients with diﬀerent clinical forms of
brucellosis, especially focusing on chronic disease.
E. coli LPS stimulation of PHA-cultured PBMCs yielded
a signiﬁcant increase in the percentage of CD4+/CD25+
T-lymphocytes in AB patients as compared to controls.
This ﬁnding comes in agreement with previous data sug-
gesting increased levels of soluble CD25 and upregulation
of CD4+/CD25+ T-cells in acutely ill brucellosis patients
[21, 37, 38]. Generally, previous in vitro and in vivo
human studies showed that LPS stimulation of normal
T-lymphocytes upregulates the CD25 expression and the
secretion of IL-2 and IFNγ by them. Thus, LPS is thought
to be a potent inducer of human T-cell proliferation and Th1
cytokineproduction[29–32]. However, increased percentage
of CD4+/CD25+ cells in AB compared to CB is rather LPS
independent, since, as we have shown previously, PHA-alone
cultures displayed similar result [21]( Figure 1). The higher
percentage of CD4+CD25+ T-cells in acute brucellosis could
be attributed to the abundant milieu of proinﬂammatory
cytokines observed in the acute disease [37, 39, 40].
On the other hand, the low frequency of CD4+/CD25+
T-lymphocytes in CB compared to AB group could be
explained as an eﬀect of chronic disease. Chronic brucella
infection could lead to a defective in vitro blastogenesis
of CD4+ T-lymphocytes due to low-proliferation response,
reduced production of IFNγ and IL-2, and switching toward
Th2 response characterized by an increased percentage of
CD3+/IL-13+ T-lymphocytes [17–20] .I th a db e e ns u g g e s t e d
that IL-13 can downregulate macrophage functions, such as
theproductionofIL-12andtheexpressionofinduciblenitric
oxide synthase in response to LPS [19, 41].
The reduction of CD4+/CD25+ T-cells percentage after
PHA plus E. coli cultures was more pronounced in chronic
relapsing brucellosis patients (CB1 subgroup), suggesting
that relapses in brucellosis might be associated with distur-
bances of IL-2/IL-2 receptor system [21].
Stimulation of human T-lymphocytes by LPS was found
to be MHC-unrestricted, but strongly dependent on costim-
ulatory signals provided by CD80/CD28 interactions [42].
CD80 seems to be crucial for the activation of T-cells by
monocytes,sincemonocytesexpressingCD86,butnotCD80
after LPS stimulation, were unable to stimulate human T-
cells [42]. Moreover, endotoxin administration to healthy
subjects increases T-lymphocytes CD28 expression [32].
Noteworthy, when PHA-cultured PBMCs were stimu-
lated by E. coli LPS, CB patients and especially CB1 subgroup
(relapsing patients) displayed signiﬁcantly lower percentage
of helper T-lymphocytes expressing CD28 costimulation
receptor in comparison to acutely ill patients, ranging at
the levels of controls. In our previous study [23], HKBA
stimulation of PHA-cultured PBMCs did not increase the
frequency of CD4+/CD28+ T-cells in chronic relapsing
brucellosis (Table 3(b)).
It could be expected that a potent pathogen-associated
molecule pattern (PAMP) stimulation, either by E. coli LPS
or HKBA, should lead to the upregulation of CD28+ T-cells
in CB1 patients. It seems that chronic relapsing brucellosis
patients are unresponsive/anergic to nonspeciﬁc or brucellar
antigens as it was shown previously [17, 19, 20, 43, 44].6 Clinical and Developmental Immunology
On the other hand, the eﬀect of E. coli on PHA-cultured
CD4+/CD28+ T-cells could be attributed to “LPS tolerance
phenomenon”, where prior sublethal exposure to LPS results
in a state of tolerance to further LPS challenge [45].
LPS tolerance is a state of altered immunity characterized
by decreased production of macrophage-derived cytokines,
suchasTNFα,IL-1β,andIL-6,aswellaslymphocyte-deriv ed
IFNγ [46, 47]. As a result LPS tolerant, macrophages have a
markedly impaired ability to induce IFNγ secretion by autol-
ogous T-cells and NK-cells [48]. It could be assumed that
in chronic relapsing brucellosis patients prior exposures to
Brucella LPS, as a result of relapses during the chronic stage,
leads to “cross tolerance” (low percentage of CD4+/CD28+
T-cells) to further in vitro E.coli LPS challenge.Nevertheless,
it is not known if chronic brucellosis patients present high
incidence of gram negative enterobacteria infections.
E. coli addition in PHA cultures did not further enhance
the increase in the percentage of CD14+/CD80+ monocytes
in both groups of brucellosis patients. The percentage of
CD14+/CD80+ cells with PHA plus LPS in PBMCs cultures
weresimilartothatobtainedwithPHAalone[23](Figure 1).
It could be speculated that patients monocytes display
maximal activation when exposed to PHA in cultures and
cannot be further activated by E. coli LPS addition. The
inﬂammatory microenvironment of the infection may also
contribute to this eﬀect [49, 50]. Speciﬁcally, in chronic
brucellosis patients, high percentage of CD14+/CD80+
monocytes in PHA and PHA plus E. coli LPS cultures
might compensate for an ineﬀectual CD4+ T-cell response
characterizing these form of disease [17–21].
Previously, we stimulated PHA-cultured PBMCs from
brucellosis patients with HKBA in order to investigate
any possible eﬀect of brucellar antigen/s (mainly LPS)
on the expression of CD25 and CD80/CD28 costimula-
tion molecules [23]. We used whole cells of HKBA in
PHA cultures in order to evaluate the immunomodulative
potential of the total brucellar antigenic structure. HKBA
addition in comparison to E. coli LPS stimulation led to a
signiﬁcant reduction of CD4+/CD25+ T-lymphocytes and
CD14+/CD80+monocytesPBMCsinadose-relatedmanner
supporting an immunomodulating eﬀect of brucella on
human PBMCs (Figure 1)[ 23].
Actually, in human macrophages, smooth LPS pro-
tects Brucella from phagosome-lysosome fusion, bactericidal
cationic peptides, and complement attack and, moreover,
is able to induce IL-10 (anti-Th1 cytokine) by PBMCs
of healthy individuals [8, 24, 51–55]. Interestingly, recent
data suggest that the smooth strains of living Brucella,
in contrast to E. coli, prevent the maturation of infected
human dendritic cells and impair their capacities to present
antigen to na¨ ıve T-cells and to secrete IL-12 [16, 26].
Moreover, other results suggest that HKBA also inhibits
major histocompatibility complex class II expression and
antigen processing in human monocytes [56].
In conclusion, T-lymphocytes of chronic brucellosis
patients retain low percentages of CD4+/CD25+ and
CD4+/CD28+ T-lymphocytes after potent stimulation of
PHA-cultured PBMCs by E. coli LPS, although the frequency
of CD14+/CD80+ monocytes remains increased. Based on
the ﬁndings revealed after the comparison of the PBMCs
PHA-cultures treated with speciﬁc (HKBA) or no speciﬁc (E.
coli LPS) antigen, we suggest that Brucella modulates both
functional arms (innate and adaptive) of human immune
system, leading to T-cell anergy and chronic infection.
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